Esperance starts EP-100 Phase I trial

09/13/2009 | Pharmaceutical Business Review Online

Esperance Pharmaceuticals has started enrolling and dosing patients in a trial of EP-100, a targeted membrane-disrupting peptide designed to locate and treat cancer cells. Preclinical studies of the drug candidate in mice showed it decreased tumors in breast, prostate, ovarian and endometrial cancer xenografts. PET imaging also showed the drug decreased tumor cells after treatment.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Director of Governmental Programs
Bluegrass Family Health
Lexington, KY